|
1) Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189-99
|
|
|
|
2) Harada H, Kondo T, Ogawa S, et al. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene. 1994; 9: 3313-20
|
|
|
|
|
|
3) Borkhardt A, Bojesen S, Haas OA, et al. The human GRAF gene is fused to MLL in a unique t(5; 11)(q31; q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci U S A. 2000; 97: 9168-73
|
|
|
|
|
4) Panagopoulos I, Kitagawa A, Isaksson M, et al. MLL/GRAF fusion in an infant acute monocytic leukemia (AML M5b) with a cytogenetically cryptic ins(5; 11)(q31; q23q23). Genes Chromosomes Cancer. 2004; 41: 400-4
|
|
|
|
|
|
5) Hu Z, Gomes I, Horrigan SK, et al. A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene. 2001; 20: 6946-54
|
|
|
|
|
|
6) Leeksma OC, Van Achterberg TA, Tsumura Y, et al. Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem. 2002; 269: 2546-56
|
|
|
|
|
|
7) Dubourg C, Toutain B, Helias C, et al. Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene. Cancer Genet Cytogenet. 2002; 134: 33-7
|
|
|
|
|
|
8) Le Beau MM, Espinosa R, 3rd, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993; 90: 5484-8
|
|
|
|
|
|
9) Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics. 1994; 19: 425-32
|
|
|
|
|
|
10) Fairman J, Chumakov I, Chinault AC, et al. Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci U S A. 1995; 92: 7406-10
|
|
|
|
|
|
11) Horrigan SK, Westbrook CA, Kim AH, et al. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996; 88: 2665-70
|
|
|
|
|
|
12) Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1. 5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997; 94: 6948-53
|
|
|
|
|
|
13) Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer. 1998; 22: 251-6
|
|
|
|
|
|
14) Horrigan SK, Arbieva ZH, Xie HY, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood. 2000; 95: 2372-7
|
|
|
|
|
|
15) Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99: 4638-41
|
|
|
|
|
|
16) Herry A, Douet-Guilbert N, Morel F, et al. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol. 2007; 78: 457-67
|
|
|
|
|
|
17) Wang L, Fidler C, Nadig N, et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica. 2008; 93: 994-1000
|
|
|
|
|
|
18) Mallo M, Arenillas L, Espinet B, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q. Haematologica. 2008; 93: 1001-8
|
|
|
|
|
|
19) List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549-57
|
|
|
|
|
|
20) List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-65
|
|
|
|
|
|
21) Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008; 451: 335-9
|
|
|
|
|
|
22) Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104: 11406-11
|
|
|
|
|
|
23) Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34＋ cells in patients with the 5q- syndrome. Br J Haematol. 2007; 139: 578-89
|
|
|
|
|
|
24) Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007; 13: 78-83
|
|
|
|
|
|
25) Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007; 110: 719-26
|
|
|
|
|
|
26) Lai F, Godley LA, Joslin J, et al. Transcript map and comparative analysis of the 1. 5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001; 71: 235-45
|
|
|
|
|